Mark Stenger
Washington State Department of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Stenger.
Clinical Infectious Diseases | 2014
Monica E Patton; Sarah Kidd; Eloisa Llata; Mark Stenger; Jim Braxton; Lenore Asbel; Kyle T. Bernstein; Beau Gratzer; Megan Jespersen; Roxanne P. Kerani; Christie J. Mettenbrink; Mukhtar Mohamed; Preeti Pathela; Christina Schumacher; Ali Stirland; Jeff Stover; Irina Tabidze; Robert D. Kirkcaldy; Hillard Weinstock
BACKGROUND Gonorrhea (GC) and chlamydia (CT) are the most commonly reported notifiable diseases in the United States. The Centers for Disease Control and Prevention recommends that men who have sex with men (MSM) be screened for urogenital GC/CT, rectal GC/CT, and pharyngeal GC. We describe extragenital GC/CT testing and infections among MSM attending sexually transmitted disease (STD) clinics. METHODS The STD Surveillance Network collects patient data from 42 STD clinics. We assessed the proportion of MSM attending these clinics during July 2011-June 2012 who were tested and positive for extragenital GC/CT at their most recent visit or in the preceding 12 months and the number of extragenital infections that would have remained undetected with urethral screening alone. RESULTS Of 21 994 MSM, 83.9% were tested for urogenital GC, 65.9% for pharyngeal GC, 50.4% for rectal GC, 81.4% for urogenital CT, 31.7% for pharyngeal CT, and 45.9% for rectal CT. Of MSM tested, 11.1% tested positive for urogenital GC, 7.9% for pharyngeal GC, 10.2% for rectal GC, 8.4% for urogenital CT, 2.9% for pharyngeal CT, and 14.1% for rectal CT. More than 70% of extragenital GC infections and 85% of extragenital CT infections were associated with negative urethral tests at the same visit and would not have been detected with urethral screening alone. CONCLUSIONS Extragenital GC/CT was common among MSM attending STD clinics, but many MSM were not tested. Most extragenital infections would not have been identified, and likely would have remained untreated, with urethral screening alone. Efforts are needed to facilitate implementation of extragenital GC/CT screening recommendations for MSM.
Sexually Transmitted Diseases | 2007
Roxanne P. Kerani; H. Hunter Handsfield; Mark Stenger; Taraneh Shafii; Ellen Zick; Devon D. Brewer; Matthew R. Golden
Objective: The objective of this study was to assess the impact of syphilis control activities in King County, Washington. Study Design: We calculated rates of early syphilis and trends in numbers of persons tested and diagnosed through screening and partner notification from 1998 to 2005. Results: Early syphilis cases increased from 38 in 1998 to 188 in 2005 with 92% occurring among men who have sex with men (MSM). Our health department conducted public awareness campaigns, increased publicly financed syphilis screening among MSM by 179%, and intensified partner notification efforts. Despite these efforts, the prevalence of syphilis among screened populations was only 1.1%, and 71% syphilis cases were diagnosed after seeking care for symptoms. The proportion of cases diagnosed through screening and partner notification did not significantly change during the evaluation period. Early syphilis incidence among MSM more than doubled between 2003 and 2005. Conclusions: New, innovative approaches to syphilis control are needed.
PLOS Medicine | 2015
Matthew R. Golden; Roxanne P. Kerani; Mark Stenger; James P. Hughes; Mark R. Aubin; Cheryl Malinski; King K. Holmes
Background Expedited partner therapy (EPT), the practice of treating the sex partners of persons with sexually transmitted infections without their medical evaluation, increases partner treatment and decreases gonorrhea and chlamydia reinfection rates. We conducted a stepped-wedge, community-level randomized trial to determine whether a public health intervention promoting EPT could increase its use and decrease chlamydia test positivity and gonorrhea incidence in women. Methods and Findings The trial randomly assigned local health jurisdictions (LHJs) in Washington State, US, into four study waves. Waves instituted the intervention in randomly assigned order at intervals of 6–8 mo. Of the state’s 25 LHJs, 24 were eligible and 23 participated. Heterosexual individuals with gonorrhea or chlamydial infection were eligible for the intervention. The study made free patient-delivered partner therapy (PDPT) available to clinicians, and provided public health partner services based on clinician referral. The main study outcomes were chlamydia test positivity among women ages 14–25 y in 219 sentinel clinics, and incidence of reported gonorrhea in women, both measured at the community level. Receipt of PDPT from clinicians was evaluated among randomly selected patients. 23 and 22 LHJs provided data on gonorrhea and chlamydia outcomes, respectively. The intervention increased the percentage of persons receiving PDPT from clinicians (from 18% to 34%, p < 0.001) and the percentage receiving partner services (from 25% to 45%, p < 0.001). Chlamydia test positivity and gonorrhea incidence in women decreased over the study period, from 8.2% to 6.5% and from 59.6 to 26.4 per 100,000, respectively. After adjusting for temporal trends, the intervention was associated with an approximately 10% reduction in both chlamydia positivity and gonorrhea incidence, though the confidence bounds on these outcomes both crossed one (chlamydia positivity prevalence ratio = 0.89, 95% CI 0.77–1.04, p = 0.15; gonorrhea incidence rate ratio = 0.91, 95% CI .71–1.16, p = 0.45). Study findings were potentially limited by inadequate statistical power, by the institution of some aspects of the study intervention outside of the research randomization sequence, and by the fact that LHJs did not constitute truly isolated sexual networks. Conclusions A public health intervention promoting the use of free PDPT substantially increased its use and may have resulted in decreased chlamydial and gonococcal infections at the population level. Trial Registration ClinicalTrials.gov NCT01665690
Public Health Reports | 2012
Lori M. Newman; Deborah Dowell; Kyle T. Bernstein; Jennifer Donnelly; Summer Martins; Mark Stenger; Jeffrey A. Stover; Hillard Weinstock
Objective. An increasing proportion of gonorrhea in the United States is diagnosed in the private sector, posing a challenge to existing national surveillance systems. We described gonorrhea epidemiology outside sexually transmitted disease (STD) clinic settings. Methods. Through the STD Surveillance Network (SSuN), health departments in the San Francisco, Seattle, Denver, Minneapolis, and Richmond, Virginia, metropolitan areas interviewed systematic samples of men and women reported with gonorrhea by non-STD clinic providers from 2006 through 2008. Results. Of 2,138 interviews, 10.0% were from San Francisco, 26.4% were from Seattle, 25.2% were from Denver, 22.9% were from Minneapolis, and 15.5% were from Richmond. A total of 1,165 women were interviewed; 70.1% (815/1,163) were ≤24 years of age, 51.3% (598/1,165) were non-Hispanic black, and 19.0% (213/1,121) reported recent incarceration of self or sex partner. Among 610 men who have sex with only women, 50.9% were ≤24 years of age, 65.1% were non-Hispanic black, 14.1% reported incarceration of self or sex partner, and 16.7% reported anonymous sex. Among 363 men who have sex with men (MSM), 20.9% were ≤24 years of age, 61.6% were non-Hispanic white, 39.8% reported anonymous sex, 35.7% reported using the Internet to meet sex partners, and 12.1% reported methamphetamine use. Conclusions. These data identified two concurrent gonorrhea epidemics in minority populations: a young, black, heterosexual epidemic with frequently reported recent incarceration, and an older, mostly white MSM epidemic with more frequently reported anonymous sex, Internet use to meet sex partners, and methamphetamine use.
Aids and Behavior | 2013
Heather Bradley; Lenore Asbel; Kyle T. Bernstein; Melanie Mattson; Preeti Pathela; Mukhtar Mohamed; Michael C. Samuel; Jane R. Schwebke; Mark Stenger; Irina Tabidze; Jonathan M. Zenilman; Deborah Dowell; Hillard Weinstock
We used data from the STD Surveillance Network to estimate HIV testing among patients being tested or treated for gonorrhea. Of 1,845 gonorrhea-infected patients identified through nationally notifiable disease data, only 51% were tested for HIV when they were tested or treated for gonorrhea. Among the 10 geographic sites in this analysis, the percentage of patients tested for HIV ranged from 22–63% for men and 20–79% for women. Nearly 33% of the un-tested patients had never been previously HIV-tested. STD clinic patients were more likely to be HIV-tested than those in other practice settings.
Sexually Transmitted Diseases | 2017
Mark Stenger; Heidi M. Bauer; Ellen Klingler; Teal R. Bell; Jennifer Donnelly; Margaret Eaglin; Megan Jespersen; Robbie Madera; Melanie Mattson; Elizabeth Torrone
Background Lacking information on men who have sex with men (MSM) for most reported cases, sexually transmitted disease (STD) programs in the United States have used crude measures such as male-to-female case ratios (MFCR) as a rule of thumb to gauge MSM involvement at the local level, primarily with respect to syphilis cases in the past. Suitability of this measure for gonorrhea incidence has not previously been investigated. Methods A random sample of gonorrhea cases reported from January 2010 through June 2013 were interviewed in selected counties participating in the STD Surveillance Network to obtain gender of sex partners and history of transactional sex. Weighted estimates of proportion of cases among MSM and proportion reporting transactional sex were developed; correlation between MFCR and proportion MSM was assessed. Results Male-to-female case ratio ranged from 0.66 to 8.7, and the proportion of cases occurring among MSM varied from 2.5% to 62.3%. The MFCR was strongly correlated with proportion of cases among MSM after controlling for transactional sex (Pearson partial r = 0.754, P < 0.0001). Conclusions Male-to-female case ratio for gonorrhea at the county level is a reliable proxy measure indicating MSM involvement in gonorrhea case incidence and should be used by STD programs to tailor their programmatic mix to include MSM-specific interventions.
Archive | 2014
Jerusha E. Barton; Jim Braxton; Darlene W. Davis; Alex de Voux; Elaine W. Flagg; LaZetta Grier; Alesia Harvey; Sarah Kidd; Robert D. Kirkcaldy; Kristen Kreisel; Eloisa Llata; Rodney J. Presley; Viani Ramirez; Fred. Rivers; Michelle Rose; Charnetta Smith; Mark Stenger; Timothy Tilert; Elizabeth Torrone; Hillard Weinstock; Emily J. Weston
Archive | 2014
Jim Braxton; Delicia Carey; Darlene W. Davis; Alison Footman; Elaine W. Flagg; LaZetta Grier; Alesia Harvey; Kathleen Hutchins; Sarah Kidd; Jennine Kinsey; Robert D. Kirkcaldy; Eloisa Llata; Robert J. Nelson; Fred. Rivers; Mark Stenger; John Su; Elizabeth Torrone; Hillard Weinstock
Sexually Transmitted Diseases | 2018
Mark Stenger; Heidi M. Bauer; Ellen Klingler; Teal R. Bell; Jennifer Donnelly; Margaret Eaglin; Megan Jespersen; Robbie Madera; Melanie Mattson; Elizabeth Torrone
Sexually Transmitted Diseases | 2018
Viani Ramirez; Emily Han; Julie Stoltey; Trang Quynh Nguyen; Preeti Pathela; Laura Tourdot; Jaime Walters; Teal R. Bell; Elizabeth Torrone; Mark Stenger